[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334263-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334263-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","satb2-is-an-emergent-biomarker-of-anaplastic-thyroid-carcinoma-a-series-with-comprehensive-biomarker-and-molecular-studies","SATB2 is an Emergent Biomarker of Anaplastic Thyroid Carcinoma - A Series with Comprehensive Biomarker and Molecular Studies","","Anaplastic thyroid carcinoma (ATC) is a rare, aggressive malignancy composed of undifferentiated tumor cells with heterogeneous histologic morphologies, making diagnosis difficult. ATC commonly shows loss of thyroglobulin and TTF1 with cytokeratin and PAX8 expression. This study evaluates SATB2 as an immunohistochemical marker by quantifying variable SATB2 mRNA in ATCs and assessing SATB2, PAX8, pancytokeratin, claudin-4, and TTF1 in 23 cases, including cases lacking either SATB2 or PAX8, and compares findings with differentiated thyroid cancers where SATB2 is absent.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/satb2-is-an-emergent-biomarker-of-anaplastic-thyroid-carcinoma-a-series-with-comprehensive-biomarker-and-molecular-studies/334263/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/satb2-is-an-emergent-biomarker-of-anaplastic-thyroid-carcinoma-a-series-with-comprehensive-biomarker-and-molecular-studies/334263.png","ImageObject",300,407,{"name":42,"@type":43},"Clementine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is diagnosing anaplastic thyroid carcinoma challenging?","Question",{"text":63,"@type":64},"ATC is composed of undifferentiated tumor cells with varied histologic morphologies, and its marker profile can be inconsistent, complicating reliable identification.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How frequently was SATB2 detected in anaplastic thyroid carcinoma cases?",{"text":68,"@type":64},"SATB2 was detected in 74% (17/23) of ATC cases by immunostaining.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the study conclude about the diagnostic value of SATB2 immunohistochemistry?",{"text":72,"@type":64},"SATB2 IHC can support the diagnosis of ATC, including situations where some other markers are missing.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334263,1790161830,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Endocrine Pathology (2024) 35:432–441  \n[https://doi.org/10.1007/s12022-024-09833-0](https://doi.org/10.1007/s12022-024-09833-0)  \nSATB2 is an Emergent Biomarker of Anaplastic Thyroid Carcinoma: A Series with Comprehensive Biomarker and Molecular Studies  \nDingani Nkosi1 · William E. Crowe1 · Brian J. Altman2,3 · Zoltán N. Oltvai1 · Ellen J. Giampoli1 · Moises J. Velez1  \nAccepted: 21 October 2024 / Published online: 5 November 2024 © The Author(s) 2024  \nAbstract  \nAnaplastic thyroid carcinoma (ATC) is a rare and aggressive thyroid malignancy typically comprised of undifferentiated tumor cells with various histologic morphologies, which makes the diagnosis challenging. These tumors commonly show loss of thyroglobulin and TTF1 with preservation of cytokeratin (67%) and Paired Box Gene 8 (PAX8) (55%) expression. Identification of a sensitive immunohistochemical stain to aid in the diagnosis of ATC would be beneficial. Immunohistochemistry (IHC) against special AT-rich sequence-binding protein 2 (SATB2) protein is a sensitive and specific marker expressed in colorectal adenocarcinoma and bone or soft tissue tumors with osteoblastic differentiation. However, SATB2 is also expressed in other sarcomatous/undifferentiated neoplasms lacking osteoblastic differentiation. Using quantitative reverse transcription PCR (RT-qPCR) we showed that there is variable expression of SATB2 mRNA expression in ATCs. To evaluate the role of SATB2 protein expression in ATC, we performed PAX8, SATB2, pancytokeratin (AE1/AE3 & CAM5.2), claudin-4 and TTF1 immunostaining on 23 cases. ATCs showed retained expression of PAX8 in 65%(15/23); SATB2 was detected in 74%(17/23); pancytokeratin was expressed in 65%(15/23); claudin-4 was expressed in 35%(8/23) and TTF1 showed expression in 13%(3/23) of cases. Furthermore, 83%(5/6) of ATCs which lacked SATB2 expression, retained PAX8 expression, while 88%(7/8) of the tumors without PAX8 expression were positive for SATB2 . Differentiated follicular cell-derived thyroid cancers (n = 30), differentiated high grade thyroid carcinoma (n = 3), and poorly differentiated thyroid carcinoma (n = 8) were negative for SATB2 immunoreactivity. Next-generation selected cases detected the commonly identified oncogenic variants including those in BRAF, RAS, TP53, and TERT promoter. Overall, we hereby demonstrate that SATB2 IHC may be used to support the diagnosis of ATC.  \nKeywords SATB2 · Anaplastic thyroid carcinoma · ATC · Thyroid cancer  \nIntroduction  \nAnaplastic thyroid carcinoma (ATC) is an aggressive malignancy, which accounts for 1–4% of all thyroid cancers[1–4] . ATC is more common in female elderly patients, primarily  \n* Moises J. Velez [Moises_Velez@URMC.Rochester.edu](Moises_Velez@URMC.Rochester.edu)  \n1 Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA  \n2 Department of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA  \n3 Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA  \nover 60 years of age [5, 6]. The majority of the patients with anaplastic thyroid carcinoma have distant metastasis at the time of diagnosis with a median survival of 1 to 6 months [2, 5, 6]. Currently, a multidisciplinary therapeutic approach comprising of surgery, radiation, chemotherapy, and targeted therapies is recommended in the treatment of ATC [3 , 5, 6] .  \nATC is often composed of undifferentiated cells with variant or heterogeneous histologic morphologies. Some of the common histological patterns in ATC include spindle cell morphology, pleomorphic morphology, osteoclast-like giant cell-rich and epithelioid-squamous morphology [2, 3] . Consequently, ancillary immunohistochemical stains show variable expression of different markers in ATC. The neoplastic cells are usually negative for thyroglobulin (96% of cases), calcitonin, and thyroid transcription factor 1 (TTF1)(70% of cases); b","cbCaimxbbX6GnWHE","https://ap.wps.com/l/cbCaimxbbX6GnWHE","pdf",2085963,"English","# Abstract\n# Introduction\n# SATB2 Biology and Diagnostic Rationale\n# Case Series and Immunostaining Strategy\n# Results in ATC and Differential Diagnosis\n# Molecular Variant Assessment\n# Conclusion","[{\"question\":\"Why is diagnosing anaplastic thyroid carcinoma challenging?\",\"answer\":\"ATC is composed of undifferentiated tumor cells with varied histologic morphologies, and its marker profile can be inconsistent, complicating reliable identification.\"},{\"question\":\"How frequently was SATB2 detected in anaplastic thyroid carcinoma cases?\",\"answer\":\"SATB2 was detected in 74% (17/23) of ATC cases by immunostaining.\"},{\"question\":\"What does the study conclude about the diagnostic value of SATB2 immunohistochemistry?\",\"answer\":\"SATB2 IHC can support the diagnosis of ATC, including situations where some other markers are missing.\"}]","SATB2 is an Emergent Biomarker of Anaplastic Thyroid Carcinoma - A Series with Comprehensive Biomarker and Molecular Studies | PDF",1790006062,25]